Clinical Trials Using Everolimus

Clinical trials are research studies that involve people. The clinical trials on this list are studying Everolimus. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 26-35 of 35

  • Letrozole, Everolimus, and Anti-Endoglin Chimeric Monoclonal Antibody TRC105 in Treating Postmenopausal Patients with Hormone-Receptor Positive or HER2 Negative Breast Cancer That Can Be Removed by Surgery

    This phase I / II trial studies the side effects and best dose of anti-endoglin chimeric monoclonal antibody TRC105 and everolimus when given together with letrozole in treating patients with hormone-receptor positive or human epidermal growth factor receptor 2 (HER2) negative breast cancer that has not spread or spread from where it started to nearby tissue and can be removed by surgery. Anti-endoglin chimeric monoclonal antibody TRC105 may stop the growth of tumor cells by blocking the growth of new blood vessels necessary for tumor growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving anti-endoglin chimeric monoclonal antibody TRC105, everolimus and letrozole may work better in treating patients with breast cancer.
    Location: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama

  • Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients with Locally Advanced TNBC with Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative

    This phase II trial studies how well pegylated liposomal doxorubicin, bevacizumab, and everolimus work in treating patients with triple-negative breast cancer with tumors predicted insensitive to standard chemotherapy. Drugs used in chemotherapy, such as pegylated liposomal doxorubicin, work in different ways to stop the growth of tumor cells by stopping them from dividing. Immunotherapy with monoclonal antibodies, such as bevacizumab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pegylated liposomal doxorubicin together with bevacizumab and everolimus may kill more tumor cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

    This phase I trial studies the side effects and best dose of ceritinib and everolimus in treating patients with solid tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or to other places in the body (metastatic) or stage IIIB-IV non-small cell lung cancer. Ceritinib and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Vandetanib and Everolimus in Treating Patients with Advanced or Metastatic Cancer

    This phase I trial studies the side effects and best dose of vandetanib and everolimus when given together in treating patients with cancer that has spread to other places in the body. Vandetanib and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas

    The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and best schedule of the combination of everolimus and sorafenib that can be given to patients with malignant glioma. The goal of Phase 2 of this study to learn if the combination of everolimus and sorafenib can help to control malignant glioma. The safety of this combination will also be studied in both phases.
    Location: 2 locations

  • Everolimus in Treating Vestibular Schwannoma in Patients with Neurofibromatosis Type 2

    This phase II trial studies how well everolimus works in treating vestibular schwannoma (a tumor on the hearing / balance nerve) in patients with neurofibromatosis type 2. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Everolimus may also stop the growth of vestibular schwannoma by blocking the growth of new blood vessels necessary for tumor growth.
    Location: UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California

  • Ganitumab, Everolimus, and Panitumumab in Treating Patients with Refractory Solid Tumors

    This phase I trial studies the side effects and the best dose of ganitumab, everolimus, and panitumumab when given together in treating patients with solid tumors that has not responded to previous treatment. Monoclonal antibodies, such as ganitumab and panitumumab, can block the ability of tumors to grow and spread by blocking protein activity which is important for tumors to grow. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ganitumab with everolimus and panitumumab may kill more tumor cells.
    Location: Duke University Medical Center, Durham, North Carolina

  • Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.

    Study to allow access to everolimus for patients who are on everolimus treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator
    Location: See Clinical Trials.gov

  • Lenvatinib and Everolimus before Surgery in Treating Patients with Locally Advanced or Metastatic Kidney Cancer

    This phase I trial studies how well lenvatinib and everolimus before surgery work in treating patients with kidney cancer that has spread to nearby tissues or lymph nodes or other places in the body. Lenvatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as everolimus, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving lenvatinib and everolimus may cause kidney cancer to shrink more than either drug taken alone, thus potentially making it possible to remove the tumor with surgery.
    Location: University of Iowa / Holden Comprehensive Cancer Center, Iowa City, Iowa

  • S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer

    This randomized Phase III trial studies how well the combination of fulvestrant and everolimus together or the combination of anastrozole, fulvestrant and everolimus together, improve progression-free survival (PFS) versus fulvestrant alone.
    Location: See Clinical Trials.gov